Inovio Pharmaceuticals (INO) Posts Wider Than Expected Losses

Inovio Pharmaceuticals Stock NewsInovio Pharmaceuticals Inc (NASDAQ: INO)

Inovio Pharmaceuticals stock is straddling the previous closed; confused as to where to go following the earnings report. Today, we’ll discuss what we saw from earnings, how the market reacted to the news, and what we can expect to see moving forward. So, let’s get right to it…

Inovio Pharmaceuticals Earnings Miss The Beat

Unfortunately, the earnings report provided by INO shows that the company greatly missed expectations with regard to top line revenue and earnings per share alike. Here’s what we saw…

  • Top Line Revenue – In the quarter, revenue came in a $5.2 million; showing year over year growth of more than 100%. However, this was nowhere near the exponential growth Wall Street was expecting. As a matter of fact, estimates from analysts came in at $17 million.
  • Earnings Per Share – While analysts expected to see a loss in the first quarter, they didn’t expect losses to be so wide. INO posted losses per share at $0.18; $0.13 higher than analysts expected to see.

As I’m sure you can see from the information above, the earnings report provided by INO didn’t seem to have much positive news to share.

How INO Reacted In The Market

As mentioned above, Inovio stock seems to be straddling the previous close today. Following the release of the report, the stock fell below the previous close before recovering and making its way back up. Now, we’re starting to see downtrends again; dragging the stock into the red. Currently (11:24), INO is trading at $7.93 per share after a loss of 0.94% so far today.

What To Expect To See From Inovio Pharmaceuticals Moving Forward

I think I can safely speak for just about all investors when I say that no one likes to see missed revenue and wider than expected losses. With that said, I am expecting to see some short term declining action. However, in the long run, I still have faith in Inovio. The company continues to work on expanding its pipeline. Their also preparing to start the registration for the phase III study on VGX-3100 early next year. Not to mention, the company recently received regulatory approval to start a phase I study on INO-5150; for which patient enrollment should begin this quarter. There’s also an INO-4212 phase one study expected to start this quarter that will test the effectiveness of the Ebola immunotherapy. All in all, there is plenty to look forward to with regard to Inovio Pharmaceuticals. So, in the long run, I’m expecting to see great gains! However, keep in mind that thanks to the fact that regardless of the innovation and studies taking place, the company did miss earnings expectations; so, it’s not unlikely that we’ll see short term declines as the company recovers from the earnings miss.

What Do You Think?

Where do you think INO is headed and why? Let us know in the comments below!

Leave a Comment